SEARCH

SEARCH BY CITATION

References

  • 1
    Kraus MS, Keefe RSE. Cognition as an outcome measure in schizophrenia. Br. J. Psychiatry 2007; 191: 4651.
  • 2
    Keefe RSE, Poe M, Walker TM, Harvey PD. The Relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and real-world functional outcome. J. Clin. Exp. Neuropsychol. 2006; 28: 260269.
  • 3
    Yamauchi K, Aki H, Tomotake M et al. Predictors of subjective and objective quality of life in outpatients with schizophrenia. Psychiatry Clin. Neurosci. 2008; 62: 404411.
  • 4
    Ueoka Y, Tomotake M, Tanaka T et al. Quality of life and cognitive dysfunction in people with schizophrenia. Prog. Neuropsychopharmacol Biol. Psychiatry 2011; 35: 5359.
  • 5
    Heinrichs RW, Zakzanis KK. Neurocognitive deficits in schizophrenia; A quantitative review of the evidence. Neuropsychology 1998; 12: 426445.
  • 6
    Glahn DC, Bearden CE, Barguil M et al. The neurocognitive signature of psychotic bipolar disorder. Biol. Psychiatry 2007; 62: 910916.
  • 7
    Keefe RSE, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: Reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr. Res. 2004; 68: 283297.
  • 8
    Matsuoka H. Clinical issues of cognitive dysfunction in schizophrenia. Jpn J. Clin. Psychopharmacol. 2007; 10: 11531160 (in Japanese).
  • 9
    Savilla K, Kettler L, Galletly C. Relationships between cognitive deficits, symptoms and quality of life in schizophrenia. Aust. N. Z. J. Psychiatry 2008; 42: 496504.
  • 10
    Thurston-Snoha BJ, Lewine RR. Intact Wisconsin Card Sorting Test performance: Implications for the role of executive function in schizophrenia. Br. J. Clin. Psychol. 2007; 46: 361369.
  • 11
    Winograd-Gurvich C, Fitzgerald PB, Georgiou-Karistianis N, Millist L, White O. Inhibitory control and spatial working memory: A saccadic eye movement study of negative symptoms in schizophrenia. Psychiatry Res. 2008; 157: 919.
  • 12
    Hughes C, Kumari V, Soni W et al. Longitudinal study of symptoms and cognitive function in chronic schizophrenia. Schizophr. Res. 2003; 59: 137146.
  • 13
    Minzenberg MJ, Poole JH, Benton C, Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am. J. Psychiatry 2004; 161: 116124.
  • 14
    Peuskens J, Demily C, Thibaut F. Treatment of cognitive dysfunction in schizophrenia. Clin. Ther. 2005; 27: 2537.
  • 15
    Wciórka J, Bembenek A, Hintze B, Kühn-Dymecka A. Schizophrenic disorders – does cognitive dysfunction relate to characteristics of course and psychopathology of the illness? Psychiatr. Pol. 2006; 40: 867884.
  • 16
    Robbins TW, James M, Owen AM, Sahakian BJ, McInnes L, Rabbitt PM. A neural systems approach to the cognitive psychology of aging: Studies with CANTAB on a large sample of the normal elderly population. In: Rabbitt PM (ed.). Methodology of Frontal and Executive Function. Lawrence Erlbaum Associates, Hove, 1996; 215238.
  • 17
    Hunter R, Cameron S, Perks S, Wesnes K. The cognitive profile of unmedicated schizophrenic patients in relation to controls. J. Psychopharmacol. 1997; 11 (Suppl.): A74.
  • 18
    Cogtest plc. Cogtest(tm): Computerised Cognitive Battery for Clinical Trials. 2002. [Cited 8 Nov 2002.] Available from URL: http://www.cogtest.com
  • 19
    Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr. Res. 2004; 72: 2939.
  • 20
    Twamley EW, Woods SP, Zurhellen CH et al. Neuropsychological substrates and everyday functioning implications of prospective memory impairment in schizophrenia. Schizophr. Res. 2008; 106: 4249.
  • 21
    Tschacher W, Dubouloz P, Meier R, Junghan U. Altered perception of apparent motion in schizophrenia spectrum disorder. Psychiatry Res. 2008; 159: 290299.
  • 22
    Boldrini M, Del Pace L, Placidi GP et al. Selective cognitive deficits in obsessive-compulsive disorder compared to panic disorder with agoraphobia. Acta Psychiatr. Scand. 2005; 111: 150158.
  • 23
    Bralet MC, Falissard B, Neveu X, Lucas-Ross M, Eskenazi AM, Keefe RS. Validation of French version of the BACS (the brief assessment of cognition in schizophrenia) among 50 French schizophrenia patients. Eur. Psychiatry 2007; 22: 365370.
  • 24
    Kaneda Y, Sumiyoshi T, Keefe R, Ishimoto Y, Numata S, Ohmori T. Brief assessment of cognition in schizophrenia: Validation of the Japanese version. Psychiatry Clin. Neurosci. 2007; 6: 602609.
  • 25
    Kaneda Y, Sumiyoshi T, Nakagome K et al. The Brief Assessment of Cognition in Schizophrenia Japanese version (BACS-J). Seishin Igaku (Clinical Psychiatry) 2008; 50: 913917 (in Japanese).
  • 26
    Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987; 13: 261276.
  • 27
    Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Rating Manual. Seiwa Pub, Tokyo, 1991.
  • 28
    Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: The Calgary Depression Scale. Br. J. Psychiatry 1993; 22: 3944.
  • 29
    Kaneda Y, Fujii A, Ohmori T. Psychometric properties of the Japanese version of the Calgary Depression Scale for Schizophrenics. J. Nerv. Ment. Dis. 2000; 188: 237239.
  • 30
    Inada T. Evaluation and Diagnosis of Drug-Induced Extrapyramidal Symptoms: Commentary on the DIEPSS and Guide to Its Usage. Seiwa Pub, Tokyo, 1996 (in Japanese).
  • 31
    Matsui M, Sumiyoshi T, Arai H, Higuchi Y, Kurachi M. Cognitive functioning related to quality of life in schizophrenia. Prog. Neuropsychopharmacol Biol. Psychiatry 2008; 32: 280287.
  • 32
    Klingberg S, Wittorf A, Wiedemann G. Disorganization and cognitive impairment in schizophrenia: Independent symptom dimensions? Eur. Arch. Psychiatry Clin. Neurosci. 2006; 256: 532540.
  • 33
    Villalta-Gil V, Vilaplana M, Ochoa S et al.; NEDENA Group. Neurocognitive performance and negative symptoms: Are they equal in explaining disability in schizophrenia outpatients? Schizophr. Res. 2006; 87: 246253.
  • 34
    Bozikas VP, Kosmidis MH, Kioperlidou K, Karavatos A. Relationship between psychopathology and cognitive functioning in schizophrenia. Compr. Psychiatry 2004; 45: 392400.
  • 35
    Lindsberg J, Poutiainen E, Kalska H. Clarifying the diversity of first-episode psychosis: Neuropsychological correlates of clinical symptoms. Nord. J. Psychiatry 2009; 14: 18.
  • 36
    Daban C, Amado I, Bourdel MC et al. Cognitive dysfunctions in medicated and unmedicated patients with recent-onset schizophrenia. J. Psychiatr. Res. 2005; 39: 391398.
  • 37
    Sachdev P, Hume F, Toohey P, Doutney C. Negative symptoms, cognitive dysfunction, tardive akathisia and tardive dyskinesia. Acta Psychiatr. Scand. 1996; 93: 451459.
  • 38
    Palmer BW, Heaton RK, Jeste DV. Extrapyramidal symptoms and neuropsychological deficits in schizophrenia. Biol. Psychiatry 1999; 15: 791794.
  • 39
    Kishi T, Moriwaki M, Kawashima K et al. Investigation of clinical factors influencing cognitive function in Japanese schizophrenia. Neurosci. Res. 2010; 66: 340344.
  • 40
    Woon PS, Chia MY, Chan WY, Sim K. Neurocognitive, clinical and functional correlates of subjective quality of life in Asian outpatients with schizophrenia. Prog. Neuropsychopharmacol Biol. Psychiatry 2010; 34: 463468.
  • 41
    Seghers JP, Docherty NM. Cognitive impairments, emotion, stress, and language in schizophrenia. Psychiatry Res. 2009; 170: 97102.
  • 42
    Mutsatsa SH, Joyce EM, Hutton SB, Barnes TR. Relationship between insight, cognitive function, social function and symptomatology in schizophrenia: The West London first episode study. Eur. Arch. Psychiatry Clin. Neurosci. 2006; 256: 356363.